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Abstract
Background: Attention deficit hyperactivity disorder (ADHD) is a childhood-onset disorder characterized by a
persistent pattern of symptoms of developmentally inappropriate and impaired inattention and/or hyperactivity/
impulsivity, with difficulties often continuing into adulthood. ADHD can come with other comorbid conditions. The
aim of this study will be to quantify the prevalence and comorbidity of ADHD among children, adolescent, and adult
population in Spain.
Methods/design: We designed and registered a study protocol for an update and expansion of a systematic review
and meta-analysis of pooled prevalence data. We will include cross-sectional observational studies reporting prevalence
of ADHD in Spain and conducted in the general population, outpatient, and/or school settings. The primary outcome
will be the prevalence of ADHD. Secondary outcomes will be the prevalence of any physical or mental comorbidity in
association with ADHD. No limitations will be imposed on publication status, study conduct period, and language of
dissemination. Comprehensive literature searches will be conducted in multiple electronic databases, including
PubMed/MEDLINE, EMBASE, Scopus, Web of Science, PsycINFO, IME – Spanish Medical Index, and IBECS – Spanish
Bibliographic Index of Health Sciences. We will also search Google Scholar, dissertation databases, and conference
abstracts. Two team members will independently screen all citations, full-text articles, and abstract data. Potential
conflicts will be resolved through discussion. The methodological quality (or risk of bias) of individual studies will be
appraised using an appropriate tool. If feasible, we will conduct random effects meta-analysis. Prevalence estimates will
be stratified according to gender, age, and geographical location. Additional analyses will be conducted to explore the
potential sources of heterogeneity (e.g., methodological quality, sample size, diagnostic criteria).
Discussion: This systematic review and meta-analysis of observational data will provide an updated synthesis of the
prevalence and comorbidity of ADHD in Spain. This study will also examine factors that may explain potential
variations in prevalence data. The findings of this study will be published in a peer-reviewed journal.
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Background
Attention deficit hyperactivity disorder (ADHD) is a
childhood-onset disorder characterized by a persistent
pattern of symptoms of developmentally inappropriate
and impaired inattention and/or hyperactivity/impulsivity,
with difficulties often continuing into adulthood [1–3].
ADHD is more common in boys than in girls [1, 4] and
can often come with other conditions (the so-called co-
morbidity) [5–7]. Considerable debate exists surrounding
the diagnosis [8–13] and treatment [14–17] of ADHD.
Claims for the condition being overdiagnosed or under-
diagnosed underscore the importance of rigorous assess-
ment [1, 11]. Recent prevalence estimates suggest that
ADHD affects about 3–7% of young people worldwide
[18–23], producing considerable impact on health services
and the community [18, 24, 25]. However, prevalence esti-
mates of ADHD within and between countries often vary
widely [19, 20, 26], and reports of increases in prevalence
further fuel the controversy [19].
Systematic reviews of descriptive epidemiology are im-
portant for characterizing the amount and geographical
distribution of health problems. Meta-analysis of epi-
demiological data (whether at a national, regional or glo-
bal levels) can be useful to get more precise estimates of
disease frequency, monitor trends and changes in disease
burden over time, and establish a benchmark pooled
prevalence but also to examine whether estimates have
increased (or decreased) with publication of different
study features. Previous systematic reviews and meta-
analyses have traditionally assessed the worldwide preva-
lence of ADHD based on studies from a broad geo-
graphic distribution (e.g., North America, Europe, Asia)
[19–22]. Very few meta-analyses exist in the biomedical
literature reporting ADHD prevalence estimates at the
country level [27–29].
In 2011, members of our review team conducted a
meta-analysis of ADHD prevalence in Spain from 14 ob-
servational studies and more than 13,000 children and
adolescent participants [29]. The main findings were
published in 2012, suggesting a first pooled prevalence
estimate of 6.8% (95% confidence interval: 4.9 to 8.8%)
at the country level [29]. The 2011 review results drew at-
tention in particular to ADHD among children and ado-
lescents [30, 31], but did not include aspects such as
comorbidity or adult population. In addition, overall find-
ings were limited by clinical and methodological hetero-
geneity [29]. In recent years, several (new) epidemiological
studies have been conducted in different geographical lo-
cations and population groups [32–34]. In addition,
methods have advanced quickly; planning data extraction
and analyses and understanding of the review process
have become more sophisticated [35–41]. Therefore, we
consider it timely to update and expand on our previous
systematic review and meta-analysis [29] with much more
detailed analysis of relevant data.
The objective of this study will be to quantify the
prevalence and comorbidity of ADHD among chil-
dren, adolescent, and adult population in Spain and
to examine factors that may explain the variations in




This study protocol is part of an ongoing evidence synthesis
project on the descriptive epidemiology and surveillance of
neurodevelopmental disorders [42]. The present protocol
has been registered within the PROSPERO database (regis-
tration number: CRD42018106082) and is being reported
in accordance with the reporting guidance provided in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols (PRISMA-P) statement [39, 40]
(see checklist in Additional file 1).
Information source and literature search
The primary source of literature will be a structured
search of major electronic databases, including PubMed/
MEDLINE, EMBASE, Scopus, Web of Science, and Psy-
cINFO, but also national databases including IME – Ín-
dice Médico Español [Spanish Medical Index] and IBECS
– Índice Bibliográfico Español en Ciencias de la Salud
[Spanish Bibliographic Index of Health Sciences]). The
secondary source of potentially relevant material will be
a search of the gray or difficult to locate literature, in-
cluding two dissertation databases (TESEO – Base de
datos de Tesis Doctorales [Spanish Data Base of Doctoral
Thesis Dissertations] and ProQuest Dissertations and
Theses Database), Google Scholar, and conference ab-
stracts from selected national or local symposia on men-
tal health, neurology, and pediatrics. We will perform
hand-searching of the reference lists of included studies,
relevant reviews, national clinical practice guidelines, or
other relevant documents (e.g., official documents and
government reports). Content experts and authors who
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are prolific in the field will be contacted. The literature
searches will be designed and conducted by the review
team which includes two experienced health information
specialists. Our main literature search will be peer-
reviewed by a senior health information specialist using
the Peer Review of Electronic Search Strategies (PRESS)
checklist [41]. The search will include a broad range of
terms and keywords related to ADHD, epidemiological
studies, and the geographical area “Spain.” For the sec-
tion of geographic area, the search will be based on a
previously validated filter to minimize potential bias re-
garding the indexing of geographical items [43]. This
filter is constructed around three complementary ap-
proaches: (1) the term “Spain” and its variants in various
languages, (2) terms related mainly to region and prov-
ince place names, and (3) acronyms for regional health
services. A draft search strategy for PubMed/MEDLINE
is provided in Additional file 2.
Eligibility criteria
Studies will be selected according to the following cri-
teria: participants, condition or outcome(s) of interest,
study design, and context.
 Participants (population): We will include studies
involving children, adolescents, and adult population
(regardless of age or sex).
 Condition or outcome(s) of interest: The primary
outcome will be the prevalence of ADHD indicating
the number of people that have the disorder divided
by the population number at a given point in time.
This is often presented as a (prevalence) proportion.
We will use author-reported definitions (according
to accepted diagnostic criteria, such as the Diagnostic
and Statistical Manual of Mental Disorders [DSM] or
the International Classification of Diseases [ICD]
criteria: ICD-9: 314.00, 314.01; ICD-10: F90). Secondary
outcomes will be the prevalence of any comorbidity, in-
dicating the existence of any distinct additional (physical
or mental) condition in association with ADHD (e.g.,
according to main DSM-IV, DSM-V, ICD-9, or ICD-10
categories of diagnoses).
 Study design and context: Eligible studies will be
observational studies (cross-sectional or health
surveys) reporting prevalence data using validated or
non-validated tools and conducted in a wide range of
people in the Spanish general population, outpatient
(including data from administrative databases and
registries), and/or school settings. Cross-sectional
studies will be the most appropriate study design to
determine the prevalence of ADHD. Cross-sectional
health surveys are typically used to estimate the point
prevalence of common conditions of long duration.
We will exclude studies in hospital/inpatient clinical
settings because they are likely to be highly selected
resulting in inaccurate estimations of the “true
prevalence” of the disorder.
No limitations will be imposed on language, publica-
tion status (unpublished studies will be eligible for inclu-
sion), and study conduct period.
Screening and selection procedure
All articles identified from the literature search will be
screened by two team members independently. First, ti-
tles and abstracts of articles returned from initial
searches will be screened based on the eligibility criteria
outlined above. Second, full texts will be examined in
detail and screened for eligibility. Third, references of all
considered articles will be hand-searched to identify any
relevant report missed in the search strategy. Any dis-
agreements will be resolved by discussion to meet a con-
sensus, if necessary. A flow chart showing details of
studies included and excluded at each stage of the study
selection process will be provided [44].
Data collection
A data extraction form will be designed and used to ex-
tract equivalent information from each study report.
Information of interest will include the following:
 Study characteristics: study design, year of publication,
journal, year (or period) of study conduct, sample size,
setting (community, school or outpatient), geographical
location of study conduct: North (Galicia, Asturias,
Cantabria, Aragon, Basque Country, Navarre, La Rioja),
Mediterranean (Balearics, Catalonia, Valencia), Centre
(Castile-La Mancha, Castile-León, Madrid,
Extremadura), and South-East (Andalusia, Murcia
and Canary Islands); and other fields to capture
data relevant to the assessment of study methodological
quality (see risk of bias assessment subsection).
 Participant characteristics: population sampled, age
(e.g., mean with standard deviation, range) and
gender (e.g., percentage of female participants).
 Outcome results: definitions and measures used to
make diagnosis (e.g., symptom only checklists,
reports of diagnosis, interviews and examination)
and whether the diagnosis met the full DSM/ICD
criteria for each edition (e.g., DSM-III, DSM-IV,
DSM-V, ICD-9, ICD-10, ICD-11, other), informants
or people reporting symptoms for a diagnostic
evaluation (e.g., child, clinician, parent, teacher and/
or a combination rule), prevalence estimates (e.g.,
number of subjects with the disorder, proportion
and 95% confidence interval), and any prevalence
estimates stratified by age, gender, severity (impairment
criterion for DSM-IV), or location. The most
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conservative diagnosis will be used in those studies
reporting more than one prevalence estimate. If
outcome results (e.g., proportion and 95% confidence
interval) are not directly provided and it is feasible, we
will calculate them from the number of cases and
sample size provided in each single study.
Data extraction forms will be piloted initially on a
small number of included studies. Subsequently, each of
the included studies will be abstracted by two team
members, independently, and potential conflicts will be
resolved through discussion. Authors of primary publi-
cations (e.g., corresponding authors) will be contacted
by email for data clarifications or missing outcome data,
as necessary. First, authors will be sent an email request-
ing their missing outcome data or data clarifications.
Second, we will send three email reminders at 2-, 6-,
and 10-week intervals after the initial email. In cases
where the identified studies do not report authors’ email
addresses or include non-working email addresses, we
will search authors’ publications, PubMed, and profiles
that are publicly available (e.g., ORCID, ResearchGate,
and Google Scholar), to find contact information.
Risk of bias in individual studies
The risk of bias in individual studies will be evaluated
using a methodological quality critical appraisal checklist
proposed by the Joanna Briggs Institute (JBI) systematic
review methods manual [37, 38]. This tool for observa-
tional studies reporting prevalence data considers the
following: sample representativeness, recruitment appro-
priateness, sample size, description of subjects and
setting, coverage of data analysis, ascertainment and
measurement of the condition, thoroughness of report-
ing statistical analysis, and identification and account-
ability of potential confounding factors/subgroups (see
Additional file 3). Stars or points will be awarded for
each quality item, and the highest quality studies will be
awarded up to ten stars. Studies will be judged to be at
low risk of bias (≥ 7 points), moderate risk of bias (4–6
points), or high risk of bias (< 4 points) [42]. The risk of
bias for each individual study will be independently
assessed by two reviewers. Discrepant scores will be re-
solved by discussion and consensus. We will provide a
narrative summary of the risk of bias of the included
studies, which will be supported by a table showing the
results of the critical appraisal.
Methods for evidence synthesis
The data from each paper (e.g., study characteristics,
context, participants, outcomes and findings) will be
used to build evidence tables of an overall description of
included studies. Crude prevalence estimates (number of
cases/sample size) will be presented along with 95%
confidence intervals. If feasible and appropriate, preva-
lence data points from primary observational studies will
be used to perform random effects meta-analyses. Since
heterogeneity is expected a priori, we will estimate the
pooled prevalence and its 95% confidence interval using
the random effects model with logit transformation
and back transformation [42]. The random effects
model assumes the study prevalence estimates follow
a normal distribution, considering both within-study
and between-study variation. Forest plots will be used
to visualize pooled estimates and the extent of het-
erogeneity among studies.
We will quantify statistical heterogeneity by estimating
the variance between studies using I2 statistic [45]. The
I2 statistic is the proportion of variation in prevalence
estimates that is due to genuine variation in prevalence
rather than sampling (random) error. I2 statistic ranges
between 0 and 100% (with values of 0–25% and 75–
100% taken to indicate low and considerable heterogen-
eity, respectively). We will also report Tau2 [46] and
Cochran Q test [47] with a P value of < 0.05 considered
statistically significant (heterogeneity).
Additional analyses
If sufficient studies are identified and data points are
available, potential sources of heterogeneity will be in-
vestigated further by subgroup or meta-regression
analyses [48] according to baseline characteristics and
methodological covariates [1–4, 19, 29, 42]. We plan
to conduct analyses by gender (male vs female), age
(e.g., children vs adolescent vs adult, mid-point of age
range as continuous variable), geographical location
(e.g., North, Mediterranean, Centre, and South-East),
setting (e.g., community/school vs outpatient), sample
size (e.g., < 500, 500–1500, or > 1500 participants),
decade of publication (e.g., 1990, 2000, or 2010),
study quality (e.g., low/moderate vs high risk of bias),
diagnostic system (e.g., DSM vs ICD criteria), and
most recent diagnostic criteria (e.g., “DSM-IV/V or
ICD-10/11” vs “Not DSM-IV/V or ICD-10/11”). In
addition, we will explore prevalence trends with gender
variations (in terms of the female-to-male prevalence ra-
tios) and over time (with the year of publication as the ex-
planatory variable) using random effects meta-regression
models [29].
Meta-bias
Small study effects (or “publication bias” across studies)
will be assessed by inspection of the funnel plots for
asymmetry and with Egger’s test [49] and Begg’s test
[50], with the results considered to indicate potential
small study effects when P values are < 0.10.
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Software considerations
All analyses will be conducted in Stata version 15
(StataCorp LP, College Station, Texas, USA) [51, 52].
Patient and public involvement
We will evaluate whether the epidemiological studies in-
cluded in the systematic review had any patient and
public involvement [53, 54].
No patients and/or public were involved in setting the
research question for this study nor were they involved
in developing plans for design (or implementation) of
this protocol. No patients and/or public will be asked to
advise on interpretation or writing up of results.
Ethics, dissemination, and research integrity
No ethical approval is required for the performance of
this study. The proposed systematic review and
meta-analysis will be reported in accordance with the
reporting guidance provided in the Preferred Reporting
Items for Systematic Reviews and Meta-analyses
(PRISMA) statement [44] and the Meta-analysis Of Ob-
servational Studies in Epidemiology (MOOSE) reporting
guideline [55]. Any amendments made to this protocol
when conducting the study will be outlined and reported
in the final manuscript. Results will be disseminated
through conference presentations and publication in a
peer-reviewed journal. All data underlying the findings
reported in the final manuscript will be deposited in a
cross-disciplinary public repository—such as the Open
Science Framework (https://osf.io/) or Zenodo (https://
zenodo.org/).
Discussion
Up-to-date epidemiological evidence about levels and
trends in country-specific morbidity (such as prevalence)
is essential input into national and subnational health
policy and planning debates. In fact, the availability of
national prevalence estimates of ADHD provides oppor-
tunities to undertake further systematic assessments of
the burden of disease [18, 23, 25].
In this paper, we have presented a study protocol for
extending a systematic review with updated meta-
analysis of the prevalence and comorbidity of ADHD in
Spain. This protocol updates and expands methods for a
new systematic review that will supersede previous
meta-analyses of observational studies on this topic [29].
The improved approaches to the methods, analysis, and
refinements in epidemiological data (revisions and up-
dates, exploration of the extent of bias, heterogeneity,
and potential variations in prevalence data), as well as
the widening of scope by age (e.g., children, adolescents
and adults), causes of comorbidity (e.g., physical or men-
tal), and time considering new data (e.g., studies from
1980 to 2020) are all relevant to this study.
A key challenge is that based on knowledge from previ-
ous systematic reviews on mental health [19–24, 56, 57],
we anticipate identifying epidemiological studies with dif-
ferent features, populations, and contexts and with a vari-
able quality of reporting methods and results. This study
will identify knowledge gaps to be filled by new research.
On this regard, implications for future epidemiological
studies will be discussed in the final manuscript.
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